Trial · NCT05744466
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in body surface area (BSA) | At baseline and every 6 months up to 60 months or treatment discontinuation | |
| Primary | Investigator global assessment (IGA) response 0/1 | Up to 60 months | |
| Primary | Dermatology life quality index (DLQI) response 0/1 | Up to 60 months | |
| Primary | Time from date of treatment initiation to date of discontinuation | Up to 60 months | |
| Secondary | 75 percent improvement in Psoriasis area and severity index (PASI) score | At baseline and every 6 months up to 60 months or treatment discontinuation | |
| Secondary | PASI score response ≤ 3 | At baseline to follow-up, up to 60 months | |
| Secondary | PASI score response ≤ 5 | At baseline to follow-up, up to 60 months | |
| Secondary | PASI score change from baseline | At baseline to follow-up, up to 60 months | |
| Secondary | National psoriasis foundation (NPF) acceptable body surface area (BSA) response | At baseline to follow-up, up to 60 months | |
| Secondary | NPF target BSA response | At baseline to follow-up, up to 60 months | |
| Secondary | BSA ≤3% | At baseline to follow-up, up to 60 months | |
| Secondary | Change in investigator global assessment (IGA) score | Up to 60 months | |
| Secondary | Change in dermatology life quality index (DLQI) response | At baseline to follow-up, up to 60 months | |
| Secondary | Change in DLQI response ≤5 | At baseline to follow-up, up to 60 months | |
| Secondary | Change in visual analog scale (VAS): Itch response | At baseline to follow-up, up to 60 months | |
| Secondary | Change in VAS: Skin Pain response | At baseline to follow-up, up to 60 months | |
| Secondary | Change in VAS: Fatigue Response | At baseline to follow-up, up to 60 months | |
| Secondary | Merit-based Incentive Payment System (MIPS) Clinical Response to Oral Systemic or Biologic Medications | At baseline to follow-up, up to 60 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05744466/registered